CN1742000A - 制备若舒伐他汀的方法 - Google Patents

制备若舒伐他汀的方法 Download PDF

Info

Publication number
CN1742000A
CN1742000A CNA028301951A CN02830195A CN1742000A CN 1742000 A CN1742000 A CN 1742000A CN A028301951 A CNA028301951 A CN A028301951A CN 02830195 A CN02830195 A CN 02830195A CN 1742000 A CN1742000 A CN 1742000A
Authority
CN
China
Prior art keywords
formula
structural formula
acid
compound
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028301951A
Other languages
English (en)
Chinese (zh)
Inventor
Y·库马
H·N·P·N·梅雷
S·迪
M·雷夫克
S·沙希亚纳拉亚纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CN1742000A publication Critical patent/CN1742000A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5352—Phosphoranes containing the structure P=C-

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028301951A 2002-12-10 2002-12-10 制备若舒伐他汀的方法 Pending CN1742000A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/005213 WO2004052867A1 (en) 2002-12-10 2002-12-10 Process for the preparation of rosuvastatin

Publications (1)

Publication Number Publication Date
CN1742000A true CN1742000A (zh) 2006-03-01

Family

ID=32500442

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028301951A Pending CN1742000A (zh) 2002-12-10 2002-12-10 制备若舒伐他汀的方法

Country Status (11)

Country Link
US (1) US7566782B2 (enExample)
EP (1) EP1578733B1 (enExample)
CN (1) CN1742000A (enExample)
AT (1) ATE501126T1 (enExample)
AU (1) AU2002348881A1 (enExample)
CA (1) CA2509619A1 (enExample)
DE (1) DE60239428D1 (enExample)
DK (1) DK1578733T3 (enExample)
HU (1) HUP0500851A3 (enExample)
SI (1) SI1578733T1 (enExample)
WO (1) WO2004052867A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102358747A (zh) * 2011-08-30 2012-02-22 浙江宏元药业有限公司 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法
CN103601687A (zh) * 2013-11-25 2014-02-26 复旦大学 一种瑞舒伐他汀钠的制备方法
CN104230990A (zh) * 2014-08-15 2014-12-24 新发药业有限公司 2-((4r,6s)-6-三苯基膦烯甲叉基-2,2-二取代基-1,3-二氧六环-4-基)乙酸酯及其制备方法与应用
CN104630297A (zh) * 2014-12-10 2015-05-20 江南大学 一种酶法非水相催化合成(r)-3-tbdmso戊二酸甲单酯及其衍生物
CN105153010A (zh) * 2010-07-01 2015-12-16 柳韩洋行 HMG-CoA还原酶抑制剂及其中间体的制备方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000322A (es) 2001-07-13 2005-09-08 Astrazeneca Uk Ltd Preparacion de compuestos de aminopirimidina.
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
EP1673351A1 (en) 2004-07-13 2006-06-28 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2591439C (en) 2005-02-22 2013-03-26 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20090124803A1 (en) * 2005-03-22 2009-05-14 Pandurang Balwant Deshpande Process for preparation of rosuvastatin
US20080161560A1 (en) * 2005-04-04 2008-07-03 Pandurang Balwant Deshpande Process for Preparation of Calcium Salt of Rosuvastatin
CN1307187C (zh) * 2005-05-16 2007-03-28 浙江海正药业股份有限公司 瑞舒伐他汀及其中间体的制备方法
EP1893585A1 (en) * 2005-06-01 2008-03-05 Fermion Oy Process for the preparation of n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide
CN102807530B (zh) 2005-06-24 2015-08-05 力奇制药公司 制备不含杂质的无定型罗苏伐他汀钙的方法
CZ299215B6 (cs) * 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
MX2007004427A (es) 2005-08-16 2007-06-14 Teva Pharma Intermedio de rosuvastatina cristalina.
MX2007006647A (es) * 2005-10-04 2007-07-25 Teva Pharma Preparacion de rosuvastatina.
WO2008053334A2 (en) 2006-10-31 2008-05-08 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
WO2008072078A1 (en) * 2006-12-13 2008-06-19 Aurobindo Pharma Limited An improved process for preparing rosuvastatin caclium
EP2125754B1 (en) 2007-02-08 2012-04-11 Aurobindo Pharma Limited Process for preparation of rosuvastatin calcium
US20090069563A1 (en) * 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
KR101157314B1 (ko) 2009-06-05 2012-06-15 주식회사종근당 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
EP2336116A1 (en) 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
KR20200003219A (ko) * 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물
WO2015074328A1 (zh) * 2013-11-25 2015-05-28 复旦大学 一种瑞舒伐他汀钠的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105153010A (zh) * 2010-07-01 2015-12-16 柳韩洋行 HMG-CoA还原酶抑制剂及其中间体的制备方法
CN105153010B (zh) * 2010-07-01 2018-06-08 柳韩洋行 HMG-CoA还原酶抑制剂及其中间体的制备方法
CN102358747A (zh) * 2011-08-30 2012-02-22 浙江宏元药业有限公司 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法
CN102358747B (zh) * 2011-08-30 2012-09-19 浙江宏元药业有限公司 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法
CN103601687A (zh) * 2013-11-25 2014-02-26 复旦大学 一种瑞舒伐他汀钠的制备方法
CN104230990A (zh) * 2014-08-15 2014-12-24 新发药业有限公司 2-((4r,6s)-6-三苯基膦烯甲叉基-2,2-二取代基-1,3-二氧六环-4-基)乙酸酯及其制备方法与应用
CN104230990B (zh) * 2014-08-15 2016-05-11 新发药业有限公司 2-((4r,6s)-6-三苯基膦烯甲叉基-2,2-二取代基-1,3-二氧六环-4-基)乙酸酯及其制备方法与应用
CN104630297A (zh) * 2014-12-10 2015-05-20 江南大学 一种酶法非水相催化合成(r)-3-tbdmso戊二酸甲单酯及其衍生物
CN104630297B (zh) * 2014-12-10 2018-07-06 江南大学 一种酶法非水相催化合成(r)-3-tbdmso戊二酸甲单酯及其衍生物

Also Published As

Publication number Publication date
EP1578733A1 (en) 2005-09-28
DK1578733T3 (da) 2011-06-14
US20060149065A1 (en) 2006-07-06
HUP0500851A3 (en) 2008-02-28
WO2004052867A1 (en) 2004-06-24
AU2002348881A1 (en) 2004-06-30
DE60239428D1 (enExample) 2011-04-21
HUP0500851A2 (en) 2007-08-28
US7566782B2 (en) 2009-07-28
SI1578733T1 (sl) 2011-07-29
ATE501126T1 (de) 2011-03-15
CA2509619A1 (en) 2004-06-24
EP1578733B1 (en) 2011-03-09

Similar Documents

Publication Publication Date Title
CN1742000A (zh) 制备若舒伐他汀的方法
CN1122029C (zh) 制备辛伐他汀的方法
EP1351963A1 (en) A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
CN85109209A (zh) 氧杂环丁-2-酮类化合物的制备方法
CN104066846A (zh) 采用南极假丝酵母脂肪酶b制备手性他汀侧链中间体的方法
WO2006100689A1 (en) Process for preparation of rosuvastatin
EP2079712A2 (en) An improved process for preparing rosuvastatin calcium
CN1193022C (zh) 在制备他汀类的过程中的内酯化方法
US20080161560A1 (en) Process for Preparation of Calcium Salt of Rosuvastatin
CN1821242A (zh) 制备二羟基酸HMG－CoA还原酶抑制剂的新方法
JP4139334B2 (ja) 新規ボロネートエステル
CN1958593A (zh) 一种用于合成瑞舒伐他汀钙的中间体的制备方法
WO2008096257A1 (en) An improved process for preparation of rosuvastatin calcium
US7112604B2 (en) Process for the preparation of Atorvastatin and intermediates
CN115521260B (zh) 一种瑞舒伐他汀叔丁酯的合成方法
CN1283633C (zh) 制备辛伐他汀的方法
CN1101397C (zh) β－甲基碳代青霉烯中间体的制备
CN1835918A (zh) 外消旋2－{[2－(4－羟基苯基)乙基]硫基}－3－[4－(2－{4－[(甲磺酰基)氧基]苯氧基}乙基)苯基]－丙酸的制备方法
CN1308309C (zh) 制备β－酮酯化合物的方法
CN1765892A (zh) 一种奥利司他的制备方法
CN101048396A (zh) 制备西酞普兰和依他普仑的方法
CN1281596C (zh) 制备4－氧代四氢吡喃－2－酮的方法
US20040259946A1 (en) Novel process for stereoselective reduction of b ketoesters
CN1923792A (zh) (s)6－芳甲基－5－羟基－3－氧代－己酸叔丁酯及其制备方法
CN1733774A (zh) 一种瑞舒伐他汀钙中间体的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication